Abstract：
UNASSIGNED: To describe characteristics and acute clinical outcomes for patients with COVID-19 treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or untreated patients at highest risk per National Health Service (NHS) criteria.
UNASSIGNED: Retrospective study of non-hospitalized patients between 1 December 2021 and 31 May 2022, using data from the Discover-NOW dataset (North-West London). Included patients were aged ≥12 years and treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or untreated but expected to be eligible for early treatment per NHS highest-risk criteria. COVID-19-related and all-cause hospitalizations were reported for 28 days from COVID-19 diagnosis (index). Subgroup analyses were conducted in patients with advanced renal disease, those aged 18-64 and ≥65 years, and by period of Omicron BA.1, BA.2 and BA.5 (post-hoc exploratory) predominance.
UNASSIGNED: Overall, 1503 treated and 4044 eligible high-risk untreated patients were included. A high proportion of patients on sotrovimab had advanced renal disease (29.3%), ≥3 high-risk comorbidities (47.6%) and were aged ≥65 years (36.9%). Five of 696 (0.7%) patients on sotrovimab, <5/337 (0.3-1.2%) on nirmatrelvir/ritonavir, 10/470 (2.1%) on molnupiravir and 114/4044 (2.8%) untreated patients were hospitalized with COVID-19. Similar results were observed across all subgroups. The proportion of patients dying within 28 days of the index period was similarly low across all cohorts (<2%).
UNASSIGNED: Patients receiving sotrovimab appeared to show evidence of multiple high-risk comorbidities. Low hospitalization rates were observed for all treated cohorts across subgroups and periods of predominant variants of concern. These results require confirmation with comparative effectiveness analyses adjusting for differences in underlying patient characteristics.
UNASSIGNED: Retrospective study of non-hospitalized patients between 1 December 2021 and 31 May 2022, using data from the Discover-NOW dataset (North-West London). Included patients were aged ≥12 years and treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or untreated but expected to be eligible for early treatment per NHS highest-risk criteria. COVID-19-related and all-cause hospitalizations were reported for 28 days from COVID-19 diagnosis (index). Subgroup analyses were conducted in patients with advanced renal disease, those aged 18-64 and ≥65 years, and by period of Omicron BA.1, BA.2 and BA.5 (post-hoc exploratory) predominance.
UNASSIGNED: Overall, 1503 treated and 4044 eligible high-risk untreated patients were included. A high proportion of patients on sotrovimab had advanced renal disease (29.3%), ≥3 high-risk comorbidities (47.6%) and were aged ≥65 years (36.9%). Five of 696 (0.7%) patients on sotrovimab, <5/337 (0.3-1.2%) on nirmatrelvir/ritonavir, 10/470 (2.1%) on molnupiravir and 114/4044 (2.8%) untreated patients were hospitalized with COVID-19. Similar results were observed across all subgroups. The proportion of patients dying within 28 days of the index period was similarly low across all cohorts (<2%).
UNASSIGNED: Patients receiving sotrovimab appeared to show evidence of multiple high-risk comorbidities. Low hospitalization rates were observed for all treated cohorts across subgroups and periods of predominant variants of concern. These results require confirmation with comparative effectiveness analyses adjusting for differences in underlying patient characteristics.
摘要：
■为了描述接受索特罗韦单抗治疗的COVID-19患者的特征和急性临床结局，nirmatrelvir/ritonavir或molnupiravir，根据国家卫生服务（NHS）标准，或未经治疗的患者处于最高风险。
■使用来自Discover-NOW数据集（伦敦西北部）的数据，对2021年12月1日至2022年5月31日非住院患者进行回顾性研究。纳入的患者年龄≥12岁，接受sotrovimab治疗，nirmatrelvir/ritonavir或molnupiravir，或未经治疗，但预计符合NHS最高风险标准的早期治疗。从COVID-19诊断开始，报告了28天的COVID-19相关和全因住院(索引)。对晚期肾病患者进行亚组分析，年龄在18-64岁和≥65岁的人，以及OmicronBA.1，BA.2和BA.5（事后勘探）占主导地位。
■总的来说，包括1503名接受治疗的高风险患者和4044名合格的未治疗患者。使用sotrovimab的患者中有很高的比例患有晚期肾脏疾病（29.3％），≥3例高风险合并症（47.6％），年龄≥65岁（36.9％）。696名患者中有5名（0.7％）服用sotrovimab，<5/337（0.3-1.2%）尼马特雷韦/利托那韦，10/470（2.1%）的莫努比拉韦患者和114/4044（2.8%）的未经治疗的患者因COVID-19住院。在所有亚组中观察到类似的结果。在所有队列中，在索引期的28天内死亡的患者比例同样较低（<2％）。
■接受sotrovimab的患者似乎显示出多种高危合并症的证据。在所有亚组和主要关注变异期的所有治疗队列中观察到低住院率。这些结果需要通过调整潜在患者特征差异的比较有效性分析来确认。
■使用来自Discover-NOW数据集（伦敦西北部）的数据，对2021年12月1日至2022年5月31日非住院患者进行回顾性研究。纳入的患者年龄≥12岁，接受sotrovimab治疗，nirmatrelvir/ritonavir或molnupiravir，或未经治疗，但预计符合NHS最高风险标准的早期治疗。从COVID-19诊断开始，报告了28天的COVID-19相关和全因住院(索引)。对晚期肾病患者进行亚组分析，年龄在18-64岁和≥65岁的人，以及OmicronBA.1，BA.2和BA.5（事后勘探）占主导地位。
■总的来说，包括1503名接受治疗的高风险患者和4044名合格的未治疗患者。使用sotrovimab的患者中有很高的比例患有晚期肾脏疾病（29.3％），≥3例高风险合并症（47.6％），年龄≥65岁（36.9％）。696名患者中有5名（0.7％）服用sotrovimab，<5/337（0.3-1.2%）尼马特雷韦/利托那韦，10/470（2.1%）的莫努比拉韦患者和114/4044（2.8%）的未经治疗的患者因COVID-19住院。在所有亚组中观察到类似的结果。在所有队列中，在索引期的28天内死亡的患者比例同样较低（<2％）。
■接受sotrovimab的患者似乎显示出多种高危合并症的证据。在所有亚组和主要关注变异期的所有治疗队列中观察到低住院率。这些结果需要通过调整潜在患者特征差异的比较有效性分析来确认。
